Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -29.09
- Piotroski Score 3.00
- Grade Neutral
- Symbol (CALA)
- Company Calithera Biosciences, Inc.
- Price $0.02
- Changes Percentage (0%)
- Change -$0
- Day Low $0.02
- Day High $0.02
- Year High $0.13
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $2.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$7.94
- Trailing P/E Ratio 0
- Forward P/E Ratio 0
- P/E Growth 0
- Net Income $-18,866,000
Income Statement
Quarterly
Annual
Latest News of CALA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Legal & General sells housebuilder Cala to private equity groups
Legal & General has agreed to sell its housebuilding subsidiary Cala for £1.35 billion to Sixth Street Partners and Patron Capital. The deal includes Cala's net debt and will enable L&G to return cas...
By Yahoo! Finance | 1 day ago -
Hezbollah pager explosions, if caused by the Mossad, would be a big escalation
The detonation of thousands of pagers used by Hezbollah members, resulting in casualties, suggests a likely Mossad operation aimed at escalating tensions. The attack, though showcasing Mossad's abilit...
By The Guardian | 2 days ago -
Bolivia's iconic ex-President Evo Morales calls for anti-government march, escalates political fight
Evo Morales urges supporters to protest against President Luis Arce, escalating their power struggle in Bolivia. Arce accuses Morales of undermining democracy and risking lives, leading to tensions an...
By AP NEWS | 2 days ago
